Concepedia

Michael Berlin

MB

15

Publications

393

Citations

12

H-Index

1998

Active since

Affiliations

Arvinas (United States)(Current)

Saarland University

Heidelberg University

Merck & Co., Inc., Rahway, NJ, USA (United States)

German Centre for Cardiovascular Research

Michael Berlin is an author at Arvinas (United States) specializing in pharmacology, medicine, and biochemistry.

ORCID

Top concepts

Publications per year

1998–2024

15

Publications

15

Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers

Jennifer Cantley, Xiaofen Ye, Emma Rousseau et al. · Nature Communications · 2022 · 115 citations · Full text

Recent advances in the development of histamine H<sub>3</sub>antagonists

Michael Berlin, Christopher W. Boyce · Expert Opinion on Therapeutic Patents · 2007 · 38 citations

, , +16

A synthesis of (+)-9a-desmethoxymitomycin A via aziridinyl radical cyclization

Frederick E. Ziegler, Michael Berlin · Tetrahedron Letters · 1998 · 37 citations · Full text

, , +13

Identification of a novel, orally bioavailable histamine H3 receptor antagonist based on the 4-benzyl-(1H-imidazol-4-yl) template

Robert Aslanian, Mwangi wa Mutahi, Neng-Yang Shih et al. · Bioorganic & Medicinal Chemistry Letters · 2002 · 27 citations · Full text

PROTACs Targeting BRM (SMARCA2) Afford Selective <i>In Vivo</i> Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models

Michael Berlin, Jennifer Cantley, Mark Bookbinder et al. · Journal of Medicinal Chemistry · 2024 · 23 citations · Full text

Rows per page

1–5 of 15